A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
Clinical trial NCT07642024 · RECRUITING
Trial details
- NCT number
- NCT07642024
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-24
- Primary completion
- 2032-12-01
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.